老年脓毒症患者临床特征及预后影响因素

 目的 探讨老年脓毒症患者临床特征及影响预后的危险因素。方法 选取2020年7月-2021年9月某三级甲等医院收治的老年脓毒症患者为研究对象，记录患者的临床及实验室资料，根据患者28天预后情况分为存活组和死亡组，比较各临床指标在两组间的差异，应用二元logistic回归分析法分析影响老年脓毒症患者预后的独立危险因素，进一步绘制受试者工作特征（ROC）曲线，评估不同指标预测患者预后的价值。结果 共纳入121例患者，其中74例为脓毒症，47例为脓毒性休克。存活组92例，死亡组29例。与存活组相比，死亡组患者发生脓毒性休克、合并症个数 ≥ 2的比例均较高（P<0.05）；序贯器官衰竭评估（SOFA）评分和急性生理与慢性健康状况评估（APACHEⅡ）评分也较高，白细胞介素6（IL-6）、胱抑素C（Cys-C）、降钙素原（PCT）、凝血酶原时间（PT）和D -二聚体（D -D）表达水平均增高（均P<0.05），而淋巴细胞绝对计数（ALC）和清蛋白（ALB）表达水平降低（均P<0.01）。二元logistic回归分析显示脓毒性休克、SOFA评分、D -D及Cys-C表达水平是影响老年脓毒症患者28天预后的独立危险因素。ROC曲线分析显示SOFA评分（AUC=0.758）、D -D（AUC=0.774）、Cys-C（AUC=0.650）预测患者的预后均有一定的价值（均P<0.01），与单个指标相比，三个指标的联合检测显示出更高的预测价值（AUC=0.882）。结论 发生脓毒性休克、SOFA评分增高、D -D及Cys-C表达水平增加是导致老年脓毒症患者病死率上升的独立危险因素，SOFA评分、D -D和Cys-C的联合检测可进一步提高脓毒症患者预后的预测价值，为临床治疗和预后评估提供参考依据。     

Urological infections after endourological procedures

In the past two decades, endourological procedures such as ureteroscopy (URS) and percutaneous nephrolithotomy (PCNL) have become the mainstay of managing kidney stone disease (KSD), with URS also used for investigating upper urinary tract lesions. Post-endourological infections affect between 1% and 6% of cases. Numerous risk factors have been identified, including longer operative times and indwelling ureteric stents, but the literature is largely heterogeneous. Identification of risk factors preoperatively include the use of pre-operative urine culture, minimizing stent dwell time and targeted antibiotic use. Intraoperatively, efforts need to be made in minimizing operative times and intra-renal pressures. Although rare, urinary tract infections following endourological procedures remain a risk, with a smaller minority developing potentially deadly urosepsis. Clinical decisions on prevention and treatment of severe sepsis have to be individualized based on the risk factors. Machine learning techniques are currently being utilized to build these tools and might provide an answer in the future.     

Virulent Escherichia coli strains among Egyptian patients with acute diarrhoea versus urinary tract infection,and their antibiotic susceptibility

Background and study aimsDiarrhoea and urinary tract infection (UTI) are common clinical problems. Meanwhile, Escherichia coli (E. coli), is the commonest bacterial pathogen reported in both of them. This study aimed to evaluate the pathogenic E. coli (PEC) in stool of acute diarrhoea and urine of UTI regarding their virulence genes and their influence on the susceptibility to routinely prescribed antibiotics.Patients and methodsTwenty two stool and another 22 urine samples of patients with acute diarrhoea and UTI respectively were collected from patients admitted at Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University, Egypt. E. coli isolation, identification of their phyla; chuA, yjaA, and TspE4.C2, and further identification of 10 virulent genes; fimH, papC, papG//, papG///, papEF, afa, sfa, CNF1, iroN & hlyA was performed. Antibiotic susceptibility was studied against quinolones, gentamicin (GM), and trimethoprim-sulphamethoxazole (TMP-SMX).ResultsThe studied virulence genes were comparably detected in both pathogenic samples. In diarrheogenic E. coli (DEC); phylum A was significantly related to both ciprofloxacin (CIP) and TMP-SMX resistance, and both of the virulence genes fimH and iroN were significantly related to all the studied antibiotics resistance, while afa was significantly related to nalidixic acid (NA) resistance. In uropathogenic E. coli (UEC); phylum D was significantly related to CIP and levofloxacin resistance, and both of the virulence genes fimH and iroN were significantly related to most of the studied antibiotics resistance.ConclusionThe isolated PEC was evidently and broadly resistant to the studied antibiotics, with limited influence of their phyla and virulence genes (fimH and iroN).     

Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer

BackgroundWe use observational methods to compare impact of perioperative chemotherapy timing (ie, neoadjuvant and adjuvant) on overall survival (OS) in muscle-invasive bladder cancer because there is no head-to-head randomized trial, and patient factors may influence decision-making.Patients and MethodsUsing Surveillance, Epidemiology, and End Results-Medicare data, we identified patients receiving cystectomy for muscle-invasive bladder cancer diagnosed between 2004 and 2013. Patients were classified as receiving neoadjuvant or adjuvant chemotherapy. Propensity of receiving neoadjuvant chemotherapy was determined using gradient boosted models. Inverse probability of treatment weighted survival curves were adjusted for 13 demographic, socioeconomic, temporal, and oncologic covariates.ResultsWe identified 1342 patients who received neoadjuvant (n = 676) or adjuvant chemotherapy (n = 666) with a median follow-up of 23 months (interquartile range, 9-55 months). Inverse probability of treatment weighted adjustment allows comparison of the groups head-to-head as well as counterfactual scenarios (eg, effect if those getting one treatment were to receive the other). The average treatment effect (ie, “head-to-head” comparison) of adjuvant compared with neoadjuvant on OS was not significant (hazard ratio, 1.14; 95% confidence interval, 0.99-1.31). However, the average treatment effect of the treated (ie, the effect if the neoadjuvant patients were to receive adjuvant instead) was associated with a 33% increase in risk of mortality if they were given adjuvant therapy instead (hazard ratio, 1.33; 95% confidence interval, 1.12-1.57).ConclusionSignificant treatment selection bias was noted in peri-cystectomy timing, which limits the ability to discriminate differential efficacy of these 2 approaches with observational data. However, patients with higher propensity to receive neoadjuvant therapy were predicted to have increased OS with approach, in keeping with existing paradigms from trial data.     

“从肠论治”脓毒症截断扭转防治策略的理论与实践

脓毒症是机体应对感染失控反应所致威胁生命的器官功能障碍,其病死率居高不下,全球大约每年大约有530万患者死亡,故深入探究脓毒症的发病机制和寻找有效的治疗药物是目前医学界的重要课题。中医药治疗脓毒症具有潜在优势,本团队在继承朱良春国医大师、国家非物质文化遗产“顾氏外科”奠基人顾伯华教授学术经验基础上,通过临床实践,首次提出"从肠论治”截断扭转防治脓毒症策略,为中医药治疗脓毒症提供了新的思路。